Allarity Therapeutics, Inc. (NASDAQ:ALLR) Short Interest Update

Allarity Therapeutics, Inc. (NASDAQ:ALLR) was the recipient of a significant drop in short interest in June. As of June 30th, there was short interest totaling 80,824 shares, a drop of 53.9% from the June 15th total of 175,384 shares. Approximately 0.5% of the shares of the stock are short sold. Based on an average daily volume of 144,991 shares, the short-interest ratio is presently 0.6 days.

Allarity Therapeutics Price Performance

Shares of ALLR stock opened at $1.16 on Wednesday. The company has a market cap of $18.46 million, a PE ratio of -1.61 and a beta of 0.53. Allarity Therapeutics has a 1 year low of $0.77 and a 1 year high of $2.35. The stock’s 50 day simple moving average is $1.46 and its two-hundred day simple moving average is $1.24.

Allarity Therapeutics (NASDAQ:ALLR) last released its earnings results on Friday, May 15th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.05. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.03 million. Equities research analysts expect that Allarity Therapeutics will post -0.92 EPS for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Allarity Therapeutics in a research report on Monday, April 20th. Wall Street Zen upgraded Allarity Therapeutics to a “hold” rating in a report on Saturday, May 30th. Finally, Ascendiant Capital Markets lifted their price objective on Allarity Therapeutics from $9.75 to $10.25 and gave the stock a “buy” rating in a research note on Monday, June 8th. One research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Allarity Therapeutics has a consensus rating of “Hold” and an average target price of $10.25.

Institutional Trading of Allarity Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Jane Street Group LLC bought a new stake in Allarity Therapeutics in the second quarter worth about $27,000. XTX Topco Ltd purchased a new stake in shares of Allarity Therapeutics in the fourth quarter worth approximately $36,000. Geode Capital Management LLC grew its position in Allarity Therapeutics by 49.3% in the 2nd quarter. Geode Capital Management LLC now owns 50,650 shares of the company’s stock valued at $51,000 after acquiring an additional 16,729 shares during the last quarter. Capital Advisors Inc. OK bought a new position in Allarity Therapeutics in the 4th quarter valued at $108,000. Finally, DRW Securities LLC purchased a new stake in Allarity Therapeutics in the fourth quarter worth $133,000. 11.53% of the stock is owned by hedge funds and other institutional investors.

About Allarity Therapeutics

Allarity Therapeutics A/S (NASDAQ:ALLR) is a clinical‐stage biotechnology company focused on advancing precision medicine in oncology and other severe diseases. The company leverages predictive biomarkers and proprietary companion diagnostic tools to identify patient populations most likely to respond to its therapeutic candidates. By integrating molecular profiling early in development, Allarity aims to improve clinical trial success rates and accelerate the path to regulatory approval.

The company’s lead pipeline includes novel small‐molecule inhibitors engineered to target key pathways in solid tumors, with two primary assets currently in mid‐stage clinical trials.